About Repligen Corp
- Industry: Life Sciences Tools & Services
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.repligen.com/
Frequently Asked Questions
What is the 52-week range for RGEN?
The 52-week high is $198.87 and the 52-week low is $100.99.
What is the P/E ratio for RGEN?
The Price to Earnings (P/E) ratio is 252.04.
What is the dividend yield for RGEN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 1.98%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 5.29%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 4.38.
Analyst Recommendation Trends
Wall Street analyst consensus for RGEN over the last few months:
Latest RGEN News
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 37% over the past six months, topping the S&P 500 by 20.7 percentage points.
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
3 Unpopular Stocks Walking a Fine Line
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.
CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow
2026-09-11. The following slide deck was published by Repligen Corporation in conjunction with this event.
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead
Over the past six months, Repligen has been a great trade, beating the S&P 500 by 18.1%. Its stock price has climbed to $168.43, representing a healthy 31.7% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 1:30 PM EDTCompany ParticipantsOlivier Loeillot - President, CEO...
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
UBS Maintains Buy on Repligen, Raises Price Target to $225
UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setup
Repligen (RGEN) passes a Strong Growth screen with solid fundamentals, accelerating EPS/revenue, and a constructive technical setup. See why growth and timing align.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
Repligen (RGEN) Stock Looks Near Fair Value After Recent Rebound
Repligen stock has delivered a strong 1 year gain, yet the broader valuation checks and recent history raise questions about how much upside is left. The intrinsic value estimate from a Discounted Cash Flow (DCF) view is close to the current share price, while market-based multiples lean more expensive. Over 5 years, Repligen shares have declined about 42%, which points to a difficult longer term journey despite a healthier recent rebound. The valuation story now hinges on whether Repligen...
Software Rebound Extends Moat Index Gains
The S&P 500 gained 2.72% and reached a record high in August, with energy leading the market as crude prices rose. Read more here.
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-25 | Garland Jason K | -421 | $189.68 | $79,855 |
| 2026-09-24 | Loeillot Olivier | -4,542 | - | - |
| 2026-09-24 | Loeillot Olivier | -8,404 | - | - |
| 2026-09-24 | Loeillot Olivier | -4,542 | $190 | $862,980 |
| 2026-09-24 | Loeillot Olivier | +4,542 | $155.38 | $705,736 |
| 2026-09-24 | Loeillot Olivier | -8,404 | $190 | $1,596,760 |
| 2026-09-24 | Loeillot Olivier | +8,404 | $154.96 | $1,302,284 |
| 2026-09-21 | Loeillot Olivier | -5,426 | - | - |
| 2026-09-21 | Loeillot Olivier | -5,426 | $180 | $976,680 |
| 2026-09-21 | Loeillot Olivier | +5,426 | $141.79 | $769,353 |
| 2026-09-04 | Loeillot Olivier | -3,035 | $165.9 | $503,507 |
| 2026-09-03 | Loeillot Olivier | -2,842 | $169.61 | $482,032 |
| 2026-09-01 | Hughes Violetta | -277 | $170.02 | $47,096 |
| 2026-08-20 | Loeillot Olivier | -5,426 | - | - |
| 2026-08-20 | Loeillot Olivier | -5,426 | $180 | $976,680 |
| 2026-08-20 | Loeillot Olivier | +5,426 | $141.79 | $769,353 |
| 2026-07-16 | Garland Jason K | -530 | $150 | $79,500 |
| 2026-06-25 | Garland Jason K | -733 | $145 | $106,285 |
| 2026-05-14 | Pax Margaret | +2,239 | - | - |
| 2026-05-14 | Pax Margaret | +995 | - | - |
| 2026-05-14 | Mhatre Rohin | +2,239 | - | - |
| 2026-05-14 | Mhatre Rohin | +995 | - | - |
| 2026-05-14 | Konstantinov Konstantin | +2,239 | - | - |
| 2026-05-14 | Konstantinov Konstantin | +995 | - | - |
| 2026-05-14 | EGLINTON MANNER CARRIE | +2,239 | - | - |
| 2026-05-14 | EGLINTON MANNER CARRIE | +995 | - | - |
| 2026-05-14 | Madaus Martin D | +2,239 | - | - |
| 2026-05-14 | Madaus Martin D | +995 | - | - |
| 2026-05-14 | BARTHELEMY NICOLAS | +2,239 | - | - |
| 2026-05-14 | BARTHELEMY NICOLAS | +995 | - | - |
| 2026-05-14 | DAWES KAREN A | +2,239 | - | - |
| 2026-05-14 | DAWES KAREN A | +995 | - | - |
| 2026-05-14 | MUIR GLENN P | +2,239 | - | - |
| 2026-05-14 | MUIR GLENN P | +995 | - | - |
| 2026-05-07 | Douglass Brian Robb | -334 | $126.43 | $42,228 |
| 2026-05-07 | MUIR GLENN P | +2,434 | - | - |
| 2026-05-07 | MUIR GLENN P | +2,434 | $38.76 | $94,342 |
| 2026-04-21 | Loeillot Olivier | -3,832 | $140 | $536,480 |
| 2026-03-05 | Hughes Violetta | +2,466 | - | - |
| 2026-03-05 | Loeillot Olivier | +25,890 | - | - |
| 2026-03-05 | Loeillot Olivier | +24,134 | - | - |
| 2026-03-05 | Bylund James | +8,315 | - | - |
| 2026-03-05 | Bylund James | +7,751 | - | - |
| 2026-03-05 | Garland Jason K | +8,315 | - | - |
| 2026-03-05 | Garland Jason K | +7,751 | - | - |
| 2026-03-05 | KURIYEL RALF | +5,669 | - | - |
| 2026-03-05 | KURIYEL RALF | +5,284 | - | - |
| 2026-03-04 | Bylund James | -62 | $125.84 | $7,802 |
| 2026-03-04 | Bylund James | +125 | - | - |
| 2026-03-04 | KURIYEL RALF | -42 | $125.84 | $5,285 |
| 2026-03-04 | KURIYEL RALF | +125 | - | - |
| 2026-03-02 | Douglass Brian Robb | -221 | $124.97 | $27,618 |
| 2026-03-02 | Loeillot Olivier | -1,610 | $124.97 | $201,202 |
| 2026-03-02 | Bylund James | -2,433 | $124.97 | $304,052 |
| 2026-03-02 | Garland Jason K | -715 | $124.97 | $89,354 |
| 2026-03-02 | KURIYEL RALF | -923 | $124.97 | $115,347 |
| 2026-03-02 | Hunt Anthony | -9,897 | $124.97 | $1,236,828 |
| 2026-02-27 | Loeillot Olivier | -344 | $128.73 | $44,283 |
| 2026-02-27 | Bylund James | -1,478 | $128.73 | $190,263 |
| 2026-02-27 | Garland Jason K | -327 | $128.73 | $42,095 |
| 2026-02-27 | KURIYEL RALF | -444 | $128.73 | $57,156 |
| 2025-12-31 | Douglass Brian Robb | +2,143 | - | - |
| 2025-12-31 | Douglass Brian Robb | +2,288 | - | - |
| 2025-12-17 | DAWES KAREN A | -275 | $161 | $44,275 |
| 2025-12-16 | MUIR GLENN P | +3,366 | - | - |
| 2025-12-16 | MUIR GLENN P | +3,366 | $26.12 | $87,920 |
| 2025-12-04 | Hunt Anthony | -2,000 | - | - |
| 2025-11-25 | Loeillot Olivier | -7,041 | $170 | $1,196,970 |
| 2025-11-18 | Bylund James | -2,191 | $151.21 | $331,301 |
| 2025-11-13 | Hunt Anthony | +2,952 | - | - |
| 2025-11-13 | Hunt Anthony | +2,952 | $33.87 | $99,984 |
| 2025-11-13 | Hunt Anthony | -1,956 | $157.11 | $307,307 |
| 2025-11-13 | Hunt Anthony | -5,737 | $156.22 | $896,234 |
| 2025-11-13 | Hunt Anthony | -3,000 | $155.45 | $466,350 |
| 2025-11-13 | Hunt Anthony | -2,500 | $154.32 | $385,800 |
| 2025-11-13 | Hunt Anthony | -2,923 | $153.14 | $447,628 |
| 2025-11-13 | Hunt Anthony | -2,100 | $152.17 | $319,557 |
| 2025-11-13 | Hunt Anthony | -1,784 | $151.01 | $269,402 |
| 2025-11-12 | Hunt Anthony | -25,000 | - | - |
| 2025-11-12 | Hunt Anthony | -464 | $158.51 | $73,549 |
| 2025-11-12 | Hunt Anthony | -11,096 | $158.01 | $1,753,279 |
| 2025-11-12 | Hunt Anthony | -4,959 | $156.65 | $776,827 |
| 2025-11-12 | Hunt Anthony | -4,740 | $155.85 | $738,729 |
| 2025-11-12 | Hunt Anthony | -3,741 | $154.92 | $579,556 |
| 2025-11-12 | Hunt Anthony | +25,000 | $33.87 | $846,750 |